An announcement from Outlook Therapeutics ( (OTLK) ) is now available.
On December 3, 2024, C. Russell Trenary III resigned as CEO of Outlook Therapeutics, Inc., with Lawrence A. Kenyon stepping in as Interim CEO. Trenary’s departure is considered a termination without cause, entitling him to severance benefits. Meanwhile, Kenyon, who has no prior arrangements influencing his appointment, will lead the company temporarily as the Board seeks a new permanent CEO.
Learn more about OTLK stock on TipRanks’ Stock Analysis page.